Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 7/20 | 0.52 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.52 |
| ▸ | CSK | P41240 | 1/20 | 0.52 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 7/20 | 0.51 |
| ▸ | EGFR | P00533 | 6/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324205 | 0.93 | MAP3K20 (0.54) | KITCSF1RABL1MAP3K7EPHA2 | |
| SCHEMBL15859952 | 0.93 | BRAF (0.59) | KITABL1BRAFEGFRFGFR1 | |
| SCHEMBL15859992 | 0.88 | BRAF (0.59) | KITABL1BRAFEGFRFGFR1 | |
| SCHEMBL15860000 | 0.86 | BRAF (0.58) | KITABL1MAP3K7EPHA2CSK | |
| SCHEMBL17313592 | 0.85 | BRAF (0.56) | KITABL1MAP3K7EPHA2CSK | |
| SCHEMBL18403163 | 0.84 | CSK (0.49) | ABL1MAP3K7EPHA2CSKMAP4K2 | |
| SCHEMBL17313603 | 0.83 | ABL1 (0.57) | ABL1MAP3K7EPHA2CSKMAP4K2 | |
| SCHEMBL15860133 | 0.83 | ABL1 (0.57) | ABL1MAP3K7EPHA2CSKMAP4K2 | |
| SCHEMBL15860135 | 0.83 | ABL1 (0.57) | ABL1MAP3K7EPHA2CSKMAP4K2 | |
| SCHEMBL18403089 | 0.83 | MAPK14 (0.52) | ABL1MAP3K7EPHA2CSKMAP4K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550772-B2 | Azaindole derivatives as multi kinase inhibitors | ORIBASE PHARMA (FR) | 2017-01-24 | — | — | US | disclosed |
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | ORIBASE PHARMA (FR) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353539-A1 | AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS | MAP2K2, MAP2K5, MAP2K3 | KIT 836/4885CSF1R 1950/4885ABL1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.